Population pharmacokinetic of marbofloxacin was investigated with 52 plasma concentration-time profiles obtained after intramuscular administration of Forcyl® in cattle. Animal's status, pre-ruminant, ruminant, or dairy cow, was retained as a relevant covariate for clearance. Monte Carlo simulations were performed using a stratification by status, and 1000 virtual disposition curves were generated in each bovine subpopulation for the recommended dosage regimen of 10 mg/kg as a single injection.
Monte Carlo simulations generate virtual sets of PK parameters by random sampling of values within the distribution of parameters previously determined by a population pharmacokinetic model. Monte
Carlo simulations can generate a large number of plasma drug profiles to predict the probability of target attainment of a PK/PD threshold value under a given dosage regimen in the target population. To perform accurate MCSs, it is necessary to develop a robust population PK model including well-defined variance/covariance terms and physiologically/statistically relevant covariates explaining the IIV in the PK parameters. Another requirement for the establishment of population dose-distribution is the knowledge of the actual distribution of minimum inhibitory concentrations (MICs) against the targeted pathogens.
Finally, the essential prerequisite for such analysis is the choice of an appropriate PK/PD index able to predict the optimal efficacy of the antibiotic.
Pasteurella multocida, Mannheimia haemolytica, and Histophilus somni
are aerobic Gram-negative bacteria belonging to the Pasteurellaceae family. These species are among the most important respiratory bacterial pathogens because they are natural inhabitants of the mucosal surfaces of food-producing animals, particularly of cattle. These organisms are able to survive in the upper part of the respiratory tract of healthy animals, while in immunocompromised animals, Pasteurellaceae can colonize and invade the lungs, leading to respiratory disease.
Marbofloxacin is a third-generation quinolone antimicrobial agent with a broad spectrum of activity (Gram negative, Gram positive) already used in cattle for the treatment of respiratory infections. A new 16% solution of marbofloxacin (Forcyl®) was recently registered for the treatment of respiratory diseases in cattle at a dose level of 10 mg/kg under the SISAAB concept, single injection short action antibiotic (Grandemange, Fournel, Giboin, & Woehrlé, 2012; Valle, Schneider, Galland, Giboin, & Woehrlé, 2012) . Marbofloxacin pharmacokinetics exhibit some variability in cattle, as previously demonstrated by who showed that clearance of the drug was lower in preruminant calves than in lactating cows. Under the knowledge of IIV in the drug clearance in cattle, the present analysis intents to evaluate the scientific rationale of the SISAAB concept applied to marbofloxacin against respiratory Pasteurellaceae by the use of population PK and MCS. PK database for population analysis was generated from standard PK studies, and PD data were extracted from the Vétoquinol antimicrobial susceptibility survey program in Europe (Kroemer, Galland, Guérin-Faublée, Giboin, & Woehrlé-Fontaine, 2012) .
| MATERIALS AND METHODS

| Marbofloxacin pharmacokinetic raw data
Database for population analysis was generated pooling plasma marbofloxacin concentrations from seven standard pharmacokinetic studies performed from 2008 to 2012 in the Vétoquinol preclinical department of global drug development division in Lure, France.
Kinetic profiles of 52 healthy animals, eight pre-ruminants calves, 22 ruminants calves, and 22 lactating dairy cows, administered by intramuscular route with a 16% marbofloxacin solution (Forcyl ® ) at doses ranging from 2 to 10 mg/kg, were available.
In each study, after administration of the drug, blood samples were collected and the plasma was separated and stored at about −75°C until analysis. For determination of marbofloxacin in plasma samples, a validated high-performance liquid chromatography (HPLC) method with fluorometric detection was used as previously described (Valle et al., 2012) . The mean number of data points per individual was 17, with sampling times ranging from 0 (pre-dose) to 96 hr after administration (Table 1 ; Figure 1 ).
Characteristics of the animals used in the present analysis are given in Table 1 . Database includes five demographic variables: bodyweight, age, status (pre-ruminant, ruminant, dairy cow), sex, and breed. Data capture was performed twice by two different operators to avoid typing error. To highlight the variability in the data and assuming linearity of marbofloxacin disposition, all plasma concentrations were normalized to a standard dose of 10 mg/kg, corresponding to the recommended dosage regimen of Forcyl® in cattle ( Figure 1 ).
| Population pharmacokinetic analysis
The population pharmacokinetics of marbofloxacin was evaluated using nonlinear, mixed-effect modeling as implemented in Phoenix A bicompartment pharmacokinetic model for intramuscular administration with first-order absorption rate (Ka) was selected as structural model. As only extravascular data were available in the database, total clearance, distribution clearance, volume of the central compartment, and volume of the distribution compartment were estimated as a ratio of the bioavailability value (F) (apparent clearances and volumes: CL/F; CL 2 /F; V/F;V 2 /F).
Interindividual variability (IIV) was assessed assuming a log-normal distribution of individual pharmacokinetic parameters. For instance, the CL/F of the ith animal was written as Equation (1): where θ CL/F is the population clearance, and (η CL/F ) i is the deviation from the population value for the i th animal. (η CL/F)i is a random variable following a normal distribution with a mean of 0 and a variance of ω 2 CL∕F. The following equation was used to convert variance term to a coefficient of variation (CV%) describing the IIV of the PK parameter in the original scale (Equation (2)):
For residual variability, a proportional error model was retained (Equation (3)).
(1)
where C(t) i is the measured concentration value of the ith animal at time t; C pred (t) i is the model predicted plasma concentration value of the ith animal at time t, and ϵ ti is a normally distributed random variable with a mean of zero and a variance of σ 2 .
A covariate analysis was conducted by comparing nested models based on the likelihood ratio test (LRT where θ 1 and θ 2 represent the change in drug clearance in animals belonging to ruminant or dairy cow status, respectively.
For sex, a dichotomous categorical covariable, code was 0 for male and 1 for female.
A covariate was kept in the analysis if the decrease in objective function was significant. For this forward approach, a criterion of p < .01 was applied for the LRT. All significant covariates were then Animals n = 8 n = 10 n = 6 n = 6 n = 6 n = 10 n = 6 Sex female n = 4 n = 5 n = 3 n = 3 n = 6 n = 10 n = 6 male n = 4 n = 5 n = 3 n = 3 ---Mean age ± SD (months) 1.5 ± 0.2 10.8 ± 2.0 16.0 ± 6.4 18.9 ± 8.7 57.6 ± 17.0 69.9 ± 26.6 111.6 ± 31.9
Mean weight ± SD (kg) 67. 
| Monte Carlo simulations (MCSs)
Monte Carlo simulations (MCSs) were performed with Phoenix NLME® version 1.2 using parameters of the final population PK model selected in the previous step. As animal's status was retained as a relevant covariate, a stratification by status was implemented for simulations. For each status, a virtual population of 1000 animals was generated: 1000 pre-ruminants, 1000 ruminants, and 1000 dairy cows. Plasma marbofloxacin concentration-time profiles were simulated for intramuscular administrations of a dose of 10 mg/kg with a step of 0.25 hr. For each simulated kinetic profile, area under the concentration time curve over 24 hr after administration (AUC 0-24 hr )
was computed by non-compartmental analysis using the linear trapezoidal rules.
| Microbiological data
Distribution of minimum inhibitory concentrations (MICs) of marbofloxacin against the pathogens of Pasteurellaceae family involved in bovine respiratory disease (BRD) was extracted from a previously published marbofloxacin susceptibility survey (Kroemer et al., 2012) . 
| PK/PD integration
Pharmacokinetic/pharmacodynamic (PK/PD) integration was performed by use of standard Excel ® spreadsheets (Excel ® 2013, Microsoft Corporation, Redmond, Washington).
The ratio AUC 0-24 hr /MIC was selected as the PK/PD index for the evaluation of the clinical efficacy of marbofloxacin against targeted pathogens (Nielsen & Friberg, 2013) . The ratio AUC 0-24 hr /MPC was considered as a surrogate marker of the risk of resistance development.
The AUC 0-24 hr obtained by MCSs was corrected for protein binding before PK/PD integration. A plasma protein binding of 26.2% for pre-ruminants and 32.5% for ruminant and dairy cows was considered (company data obtained from equilibrium dialysis, not shown).
An AUC 0-24 hr /MIC greater than 125 hr is generally accepted to be predictive of clinical efficacy of fluoroquinolones (Mckellar, Sanchez Bruni, & Jones, 2004; Toutain, Del Castillo, & Bousquet-Mélou, 2002; Valle et al., 2012) . However, this approach is a simplification of the PK/ PD relationship. For a given drug, the value of the AUC 0-24 hr /CMI ratio required for effect is dependent on the bacterial species and should be experimentally determined as accurately as possible. Threshold values lower than 125 hr for the ratio AUC 0-24 hr /MIC can be found in the literature for marbofloxacin against bovine respiratory pathogens (Aliabadi & Lees, 2002; Illambas et al., 2013) . Furthermore, a ratio AUC 0-24 hr /MPC greater than 25 hr was used by Vilalta et al. (2014) .
as an index reflecting the limitation of development of resistance for evaluation of marbofloxacin in pigs. Therefore, threshold values for the PK/PD indices ranging from 25 hr to 125 hr were considered at the following steps. The probability of target attainment (PTA) (Mouton, Dudley, Cars, Derendorf, & Drusano, 2005) (Mouton et al., 2005) . Cumulative fraction of response was computed for each bacterial strain, and each population.
Cumulative fraction of response reports the proportion of animals in the population achieving an AUC 0-24 hr /MIC greater than a threshold value taking into account both the MIC distribution against the bacteria and the AUC distribution in the population of interest.
| RESULTS
| Population pharmacokinetic model
A bicompartment pharmacokinetic model for intramuscular administration with first-order absorption rate (Ka) accurately described the disposition of marbofloxacin in cattle.
A full block variance-covariance Ω (omega) matrix was initially assumed on all structural parameters, followed by inspection of the correlation among the Etas (η). Individual etas for the apparent volume of the distribution compartment (V 2 /F) and the apparent clearance of distribution (CL 2 /F) were highly correlated (r = .8). Covariance terms between V 2 /F and CL 2 /F were estimated with a good precision (CV = 25.5%); however, this full block Ω matrix results in poor precision of other covariance terms (CVs ranging from 42% to 650%). A "shared eta (η) approach" was applied for V 2 /F and CL 2 /F, as described by Mould and Upton (Mould & Upton, 2013) . The eta for CL 2 /F was removed and replaced by a scaling factor (W) multiplied by the eta of the other parameter (ηV 2 /F), as follows (Equations (6) and (7)):
became The variance of CL 2 /F was computed according to Equation (8):
Introduction of this shared eta in the omega structure did not improve the precision of the covariance terms between others pharmacokinetic parameters (CVs ranging from 50% to 424%); therefore, a diagonal omega matrix was retained (only variance terms).
Finally, a two-compartment model with a diagonal omega matrix and a shared eta between V 2 /F and CL 2 /F was selected as base model for covariate search. Typical values and IIV(%) of pharmacokinetic parameters for the base model were as follows: θ Ka = 4.21 hr Final model parameter estimates are given in Table 2 θ:population parameter, Ka: first-order absorption rate; CL/F:apparent clearance; θ 1, θ 2 : model terms describing the change in drug clearance in ruminants and dairy cows, respectively (see Equation (5)); V/F:apparent volume of central compartment; V 2 /F:apparent volume of distribution compartment; CL 2 /F:apparent distribution clearance; W:shared eta scale factor (see Equation (7)); ε:proportional residual error; ω 2 : variance term describing deviation from the population parameter value; RSE: relative standard error; IIV: interindividual variability expressed as a coefficient of variation (See Equation (2)).
between −2 and +2, indicating no major bias in the structural model and in the residual error model. The visual predictive check (VPC) plots stratified by status given in Figure 3 show that the 90% prediction intervals adequately describe the observed concentrations at each time points. By the use of the pharmacokinetic parameters from the selected population model, 1000 virtual concentration-time profiles of pre-ruminants, ruminants, and dairy cows were generated by MCSs, for a marbofloxacin dose of 10 mg/kg.
| Prediction of positive clinical outcome
The probability of target attainment of a ratio AUC 0-24 hr /MIC greater than threshold values ranging from 25 of 125 hr was calculated for a selection of MIC values in the three simulated populations (Tables 3, 4, and 5). From the practitioners point of view, PTA represents the probability, for a given dose, of achieving an adequate pharmacodynamic exposure against a bacteria whose MIC is known. In pre-ruminants, the probability of achieving a ratio AUC 0-24 hr /MIC > 125 hr at a dose of 10 mg/kg is greater than 90% when considering MIC values up to 0.25 μg/ml. In ruminants and dairy cows, a PTA > 90% for the PK/ PD efficacy ratio was predicted for a MIC ≤ 0.12 μg/ml. 
| Prediction of prevention of antimicrobial resistance
The probability of target attainment of a ratio AUC 0-24 hr /MPC greater than threshold values ranging from 25 of 125 hr is given in Tables 3, 4, and 5. As previously retained by Vilalta et al. (2014) , a ratio AUC 0-24 hr / MPC greater than 25 hr was considered as a marker of antimicrobial resistance prevention.
For a dose of 10 mg/kg, the PTA of the ratio AUC 0-24 hr / MPC > 25 hr (Tables 3 and 4) is greater than 90% for MPC values ≤1 μg/ml in the pre-ruminant and ruminant populations. In dairy cows' population, a PTA > 90% is achieved for a MPC ≤ 0.5 μg/ml at the lowest dose (Table 5) . , corresponding to θ CL/F, was obtained for pre-ruminants (reference status). In other words, preruminants had a population apparent clearance about two times lower than the ones of ruminants and dairy cows. This difference is most probably due to higher elimination capacities in ruminant and dairy cows, for which direct evidence would have been obtained by determination of the "true clearance" after intravenous administration in the three populations. This finding is in accordance with previous results of , who showed that marbofloxacin clearance, after intravenous administration at a dose rate of 2 mg/kg, was lower in preruminant calves than in lactating cows. As milk accounts for <1% of drug elimination, this difference in clearance is supposed to be related to a slower urinary elimination and/or metabolic immaturity in pre-ruminant than in ruminant animals . This result is opposite to data obtained in pigs for which marbofloxacin clearance values significantly decrease as a function of age (Schneider, Paulin, Dron, & Woehrlé, 2014) . , respectively), it could be argued that the following covariate model for clearance could have been as follows (Equation (9)): with status redefined as a dichotomous categorical covariable, coded 0 for preruminants, 1 for both ruminants and dairy cows and with θ 1 representing the change in drug clearance in animals belonging to ruminant and dairy cow status. However, the likelihood ratio test was in favor of a model including 3 levels for status (as described in Equation (5)) as a significant covariate for clearance.
To highlight the variability in the data, plasma concentrations were normalized to a standard dose of 10 mg/kg. To perform such normalization, dose proportionality of the kinetics should be documented.
Linearity of marbofloxacin disposition between 5 and 20 mg/kg was shown in a study performed in ruminant calves (data not shown).
The relationship between the theoretical administered doses and the AUC INF values was significantly linear, and the pharmacokinetics of marbofloxacin were considered as proportional to the administered doses within the range of 5-20 mg/kg. However, normalization was performed in the present study across a 2-10 mg/kg range. Doseproportionally across this range seems justified, as the population pharmacokinetic analysis of the data using a linear model for clearance was able to give an accurate description of the data.
Before PK/PD integration, the AUC 0-24 hr obtained by MCSs was corrected for protein binding using internal results obtained from equilibrium dialysis. The free fraction was constant over the 0.06-6 μg/ml concentrations range investigated, but binding was slightly lower in pre-ruminants (26.2%) than in ruminant animals (32.5%). It could be hypothesized that binding capacity and/or affinity could slightly change as a function of age, as suggested for danofloxacin in calves (Mzyk, Baynes, Messenger, Martinez, & Smith, 2016 
Visual predictive check plots for pre-ruminants (a), ruminants (b), and dairy cows (c) life in calves. However, for marbofloxacin, the difference was small and was not supposed to have a significant impact on the status-related difference observed in the pharmacokinetics. Therefore, the origin of this difference was not investigated.
The present analysis intended to evaluate marbofloxacin administered as a single IM injection of 10 mg/kg for the treatment of bovine respiratory diseases caused by Pasteurellaceae bacteria (SISAAB concept, Single Injection Short Action Antibiotic (Grandemange, Fournel, et al., 2012; Valle et al., 2012) ). The PK/PD index AUC 0-24 hr /MIC was retained for prediction of efficacy. A ratio AUC 0-24 hr steady state /MIC above 125 hr, equivalent to an average plasma concentration about five times higher than the MIC over 24 hr at steady state, is accepted as predictive of positive clinical outcome for fluoroquinolones (Mckellar et al., 2004; Toutain et al., 2002) . For a multiple administration dosage regimen, AUC extrapolated to time infinity after one administration (AUC INF, 1 ), which is equal to AUC 0-24 hr steady state, could have been retained as the PK/PD index. However, for one shot administration, we are not dealing with steady-state AUC value. Using the AUC INF in the case of the single dose regimen would have overestimated average drug concentration per day. Therefore, AUC 0-24 hr after one administration was retained, as the previous work of Vilalta et al. (2014) in pigs. Other partial AUCs, for instance AUC 0-48 hr or AUC 24-48 hr , could have been considered to compute the ratio of average blood concentration relative to targeted MICs (Toutain, Bousquet-Mélou, & Martinez, 2007) . However, as observed marbofloxacin concentrations between 24 and 48 hr after injection of a 10 mg/kg dose were in the same order of magnitude as the MIC 90 of the targeted pathogens, 0-48 hr or 24-48 hr time intervals were not evaluated.
In the present analysis, a ratio AUC 0-24 hr /MIC greater than 125 hr was assumed to be synonymous of clinical success. The break point value of 125 hr for the ratio AUC 0-24 hr /MIC was shown to be correlated with bacterial cure for fluoroquinolones in human (Forrest et al., 1993; Schentag, 2000) . Nevertheless, despite it is widely accepted by the veterinary scientific community for fluoroquinolones, this value has not been validated for marbofloxacin for the treatment of cattle pneumonia. Moreover, some lower values could be found in the literature. For example, using ex vivo data, Aliabadi and Lees found that the eradication response of a calf isolate of M. haemolytica correspond to a AUC 0-24 hr /MIC value of 119.6 hr for marbofloxacin in serum (Aliabadi & Lees, 2002) . More recently, Illambas et al. (2013) have determined in calf serum mean ratios AUC 0-24 hr /MIC of 64.36 hr and 79.24 hr to achieve a 4-log 10 reduction in counts (corresponding MIC values used for the analyses, extracted from an epidemiological survey, were generated in Mueller-Hinton broth, whereas it is generally recommended for dosage regimen determination to used MIC data determined in biological fluids. It could be argued that a scaling factor should have been used to transform epidemiological data into relevant MIC concentrations for PK/PD integration. The AUC 0-24 hr values were corrected for protein binding, but the lack of observation to support the assumption that bound fraction account for the whole part of differences between biological fluids and broth is an important limitation of our work.
In the same way, contribution of natural body defenses was not taken into account for prediction of clinical outcome and constitutes another limitation of the present study.
The present analysis was conducted with plasma concentrations from healthy animals. Ismail & El-Kattan (2007) showed that marbofloxacin AUC 0-24 hr was significantly higher in ruminants calves infected with
Mannheimia haemolytica than in healthy ones. In the same way, Thomas, Deleforge, Boiramé, & Espinasse (1994) Histophilus somni ranged from 85% to 100% in the three populations at the dose of 10 mg/kg when considering a value of 125 hr for the ratio AUC 0-24 hr /MIC. From the practitioners point of view, CFR is the probability, for a given dose, of achieving an adequate exposure against a specific bacterial population (in other words, the probability of positive clinical outcome when using a given antibiotic dose against a pathogen whose etiology is known, but its MIC is unknown). Therefore, the present analysis suggests that marbofloxacin administered as a single dose of 10 mg/kg is an appropriate empiric anti-infective to treat respiratory infections caused by pathogens of Pasteurellaceae family. The field efficacy of the 10 mg/kg dose as a single administration (Forcyl ® ) for treatment of bovine respiratory disease caused by Pasteurella multocida and Mannheimia haemolytica has also been confirmed in a clinical trial (Grandemange, Fournel, et al., 2012) .
In the present analysis, the ratio between the AUC 0-24 hr and the MPC was used as a PK/PD index describing the likelihood of emergence of antimicrobial resistance. The PTA of the threshold value AUC 0-24 hr / MPC > 25 hr associated with the prevention of antimicrobial resistance was calculated, as previously done in pigs (Vilalta et al., 2014) . Under the recommended 10 mg/kg dose of Forcyl ® , the PTA was shown to be greater than 90% considering a MPC value ≤1 μg/ml in pre-ruminants and ruminants or a MPC value ≤0.5 μg/ml in dairy cows. In the present analysis, it would have been interesting to estimate CFRs for the AUC 0-24 hr /MPC index. To the best of our knowledge, MPC distribution data are not available for respiratory pathogens in cattle and it will be a major issue for further studies. Nevertheless, the PTA values obtained at each MPC could be weighed by MPC distribution of pathogens, at a later stage, when such data will have been generated. As distribution of
MICs is published, the AUC/MIC ratio could also have been considered to compute CFRs for a PK/PD index related to prevention of antibiotic resistance (e.g., AUC 0-24 hr /MIC > 250 hr). Nevertheless, MPCs and MICs values are not proportional when multiple isolates are studied and prediction of emergence of resistance based on MIC is less accurate than those based on direct measurement of MPC (Zhao & Drlica, 2008) .
T A B L E 5 Probability of target attainment (PTA%) of PK/PD threshold values the dairy cows' population for marbofloxacin intramuscular administration of 10 mg/kg 
| CONCLUSIONS
In conclusion, the population PK model MCs based PK/PD approach permitted to compute the CFRs for efficacy of marbofloxacin for the treatment of cattle pneumonia. From the practitioners point of view, CFR is an interesting tool for prediction of clinical outcome of a drug under a given dosage regimen without knowledge of the clinical pathogen's susceptibility. When considering the ratio AUC 0-24 hr / MIC > 125 hr for prediction of positive clinical outcome, marbofloxacin administered as a single 10 mg/kg dose appears to be an appropriate empiric treatment of bovine respiratory disease caused by
Pasteurellaceae. Regarding prevention of resistances, the PTA of the ratio AUC 0-24 hr /MPC > 25 hr was greater than 90% up to MPC values of 1 μg/ml in pre-ruminants and ruminants and 0.5 μg/ml in dairy cows. 
